Veru Stock Could Retrace Week's 45% Gain As FDA Panel Votes Against COVID-19 Drug
Veru Inc. (NASDAQ:VERU) shares could gap-open lower on Thursday following a negative Food and Drug Administration Panel verdict for its COVID-19 t...
Source: businessinsider.com